Artificial intelligence (AI) offers potential support in patient-clinician interactions, but its impact on such communication remains unexplored. In this study, ChatGPT was compared with two pancreatic surgeons in responding to ten pancreatic cancer surgery-related questions, co-designed with the Patient Advisory Board of the Surgical Society's Study Center. A blind evaluation of these responses, considering content congruency and clarity for non-specialists, was conducted by patients and surgeons. From June 23 to July 21, 2023, 24 patients and 25 surgeons participated, of which eleven patients and ten surgeons completed the survey in full. Utilizing a quantitative scale from 1 (strong-disagreement) to 5 (full-agreement), consensus was observed among patients and specialists concerning the content delivered by ChatGPT. The metrics for comprehensibility to a non-specialist audience consistently showed positive reception. In the evaluation of empathetic resonance, ChatGPT's responses mirrored those of the surgeons in the patient's view. A significant proportion ranked Surgeon 1's contributions foremost, followed closely by ChatGPT. This study demonstrates that surgeons and ChatGPT answer common queries from patients regarding pancreatic cancer surgery comparable regarding reliability, lay comprehension and empathy as evaluated by patients and surgical experts. These findings highlight the potential of AI in enhancing patient-provider interactions.
Background: Acinar cell carcinomas (ACC) belong to the exocrine pancreatic malignancies. Due to their rarity, there is no consensus regarding treatment strategies for resectable ACC.Methods: This is a retrospective multicentric study of radically resected pure pancreatic ACC. Primary endpoints were overall survival (OS) and disease-free survival (DFS). Further endpoints were oncologic outcomes related to tumor stage and therapeutic protocols. Results: 59 patients (44 men) with a median age of 64 years were included. The median tumor size was 45.0 mm. 61.0% were pT3 (n = 36), nodal positivity rate was 37.3% (n = 22), and synchronous distant metastases were present in 10.1% of the patients (n = 6). 5-Years OS was 60.9% and median DFS 30 months. 24 out of 31 recurred systemically (n = 18 only systemic, n = 6 local and systemic). Regarding TNM-staging, only the N2-stage negatively influenced OS and DFS (p = 0.004, p = 0.001). Adjuvant treatment protocols (performed in 62.7%) did neither improve OS (p = 0.542) nor DFS (p = 0.159). In 9 cases, radical resection was achieved following neoadjuvant therapy.Discussion: Radical surgery is currently the mainstay for resectable ACC, even for limited metastatic disease. Novel (neo)adjuvant treatment strategies are needed, since current systemic therapies do not result in a clear survival benefit in the perioperative setting.